PTJ
MRNA icon

Paul Tudor Jones’s Moderna MRNA Stock Holding History

Paul Tudor Jones’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Sell
39,200
-112,900
-74% -$5.84M ﹤0.01% 1723
2026
Q1 		$7.73M Sell
152,100
-332,900
-69% -$15.5M 0.01% 896
2025
Q4 		$14.3M Sell
485,000
-422,800
-47% -$11.5M 0.03% 545
2025
Q3 		$23.4M Sell
907,800
-229,600
-20% -$6.4M 0.04% 369
2025
Q2 		$31.4M Buy
1,137,400
+624,300
+122% +$16.4M 0.07% 220
2025
Q1 		$14.5M Sell
513,100
-44,600
-8% -$1.58M 0.05% 313
2024
Q4 		$23.2M Buy
557,700
+396,800
+247% +$19M 0.09% 125
2024
Q3 		$10.8M Buy
160,900
+31,400
+24% +$2.88M 0.04% 380
2024
Q2 		$15.4M Buy
129,500
+81,300
+169% +$10.3M 0.08% 234
2024
Q1 		$5.14M Sell
48,200
-2,700
-5% -$272K 0.03% 610
2023
Q4 		$5.06M Buy
50,900
+43,300
+570% +$3.64M 0.04% 632
2023
Q3 		$785K Buy
+7,600
New +$848K 0.01% 1435

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Paul Tudor Jones's MRNA Position: Q2 2026 in Review

Paul Tudor Jones sold out of Moderna (MRNA) in Q2 2026, closing a stake of 143,115 shares — an estimated $7.4M sold.

Paul Tudor Jones first reported a position in MRNA in Q3 2020 and held it in 18 quarters. The position peaked at $14.8M in Q2 2025. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Paul Tudor Jones reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 143,115 Moderna shares in Q2 2026, an estimated $7.4M.
  • Paul Tudor Jones first reported a position in Moderna in Q3 2020 and held it in 18 quarters.
  • Paul Tudor Jones's Moderna position peaked at $14.8M in Q2 2025.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.